In 2020, Humira generated $19.83 billion in revenue for a 3.5 percent increase over 2019.
The three top drugs by 2020 revenue for 13 leading drugmakers:
AbbVie
- Humira — $19.83 billion
- Imbruvica — $5.31 billion
- Botox — $2.50 billion
Merck
- Keytruda — $14.38 billion
- Gardasil/Gardasil 9 — $3.94 billion
- Januvia — $3.31 billion
Bristol Myers Squibb
- Revlimid — $12.11 billion
- Eliquis — $9.17 billion
- Opdivo — $6.99 billion
Pfizer
- Prevnar 13/Prevenar 13 — $5.85 billion
- Ibrance — $5.39 billion
- Eliquis — $4.95 billion
Johnson & Johnson
- Stelara — $7.71 billion
- Darzalex — $4.19 billion
- Imbruvica — $4.13 billion
Gilead
- Biktarvy — $7.26 billion
- Genvoya — $3.34 billion
- Veklury — $2.81 billion
Amgen
- Enbrel — $5 billion
- Prolia — $2.76 billion
- Neulasta — $2.29 billion
Novartis
- Cosentyx — $4 billion
- Gilenya — $3 billion
- Entresto — $2.5 billion
Eli Lilly
- Trulicity — $5.07 billion
- Humalog — $2.63 billion
- Alimta — $2.33 billion
Sanofi
- Dupixent — $4.04 billion
- Lantus — $3.04 billion
- Influenza vaccine — $2.82 billion
AstraZeneca
- Tagrisso — $4.33 billion
- Symbicort — $2.72 billion
- Imfinzi — $2.04 billion
Novo Nordisk
- Ozempic — $3.25 billion
- Victoza — $2.87 billion
- NovoRapid/NovoLog — $2.59 billion
GlaxoSmithKline
- Triumeq — $2.96 billion
- Shingrix — $2.55 billion
- Seretide/Advair — $1.97 billion
More articles on pharmacy:
NIAID: AstraZeneca’s COVID-19 vaccine data may be outdated
Pfizer to develop more mRNA vaccines
Regeneron says its COVID-19 antibody cocktail reduces hospitalization, death risk by 70%
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.